HighTower Advisors’s Tvardi Therapeutics TVRD Stock Holding History

HighTower Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,421	Closed	-$1.22M	–	2391
2018 Q3	$1.22M	Buy	1,421 +67	+5%	+$48.4K	0.01%	1040
2018 Q2	$932K	Buy	1,354 +877	+184%	+$446K	0.01%	1150
2018 Q1	$212K	Buy	+477	New	+$231K	﹤0.01%	1846
2017 Q3	–	Sell	-286	Closed	-$157K	–	2375
2017 Q2	$157K	Buy	+286	New	+$181K	﹤0.01%	1887

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's TVRD Position: Q4 2018 in Review

HighTower Advisors sold out of Tvardi Therapeutics (TVRD) in Q4 2018, closing a stake of 1,421 shares — an estimated $1.22M sold.

HighTower Advisors first reported a position in TVRD in Q2 2017 and held it in 4 quarters. The position peaked at $1.22M in Q3 2018. 134 funds tracked by Wall St. Rank hold TVRD as of Q4 2018.

HighTower Advisors reported no remaining Tvardi Therapeutics position as of Q4 2018 after selling out during the quarter.
HighTower Advisors sold 1,421 Tvardi Therapeutics shares in Q4 2018, an estimated $1.22M.
HighTower Advisors first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 4 quarters.
HighTower Advisors's Tvardi Therapeutics position peaked at $1.22M in Q3 2018.
134 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2018.

Based on HighTower Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.